Abstract
We have developed a comprehensive information platform, named KeyMolnet, for drug discovery and life science research in the post-genome era. Using KeyMolnet, we show new approaches to research into the biological mechanism in DNA microarray analysis. Thanks to the DNA microarray technology, it is now possible to obtain very large quantities of gene expression data at a time. However, it is still difficult to extract meaningful information from such large quantities of data and to analyze the relationship between gene expression data and biological function. We therefore developed an advanced tool that can generate molecular networks upon demand, and beyond signaling “cross-talks,” can connect them to physiological phenomena and medical and drug information. Here we show the methods of mechanism analysis using the DNA microarray data and KeyMolnet, as well as the possible mechanism of inducing apoptosis in the human promyelocytic leukemia cell line, HL-60, treated with 12-O-tetradecanoylphorbol 13-acetate (TPA), using the time series of gene expression data from DNA microarray experiments. KeyMolnet enables practical approaches to research into biological mechanisms, which in turn contribute to new discoveries in the medical, pharmaceutical and life sciences.
Keywords: dna microarray, proteomics, network, molecular relation, data mining, platform, apoptosis
Current Drug Discovery Technologies
Title: New Approaches to Mechanism Analysis for Drug Discovery Using DNA Microarray Data Combined with KeyMolnet
Volume: 2 Issue: 2
Author(s): Hiromi Sato, Seiichi Ishida, Kyoko Toda, Rieko Matsuda, Yuzuru Hayashi, Makoto Shigetaka, Miki Fukuda, Yohko Wakamatsu and Akiko Itai
Affiliation:
Keywords: dna microarray, proteomics, network, molecular relation, data mining, platform, apoptosis
Abstract: We have developed a comprehensive information platform, named KeyMolnet, for drug discovery and life science research in the post-genome era. Using KeyMolnet, we show new approaches to research into the biological mechanism in DNA microarray analysis. Thanks to the DNA microarray technology, it is now possible to obtain very large quantities of gene expression data at a time. However, it is still difficult to extract meaningful information from such large quantities of data and to analyze the relationship between gene expression data and biological function. We therefore developed an advanced tool that can generate molecular networks upon demand, and beyond signaling “cross-talks,” can connect them to physiological phenomena and medical and drug information. Here we show the methods of mechanism analysis using the DNA microarray data and KeyMolnet, as well as the possible mechanism of inducing apoptosis in the human promyelocytic leukemia cell line, HL-60, treated with 12-O-tetradecanoylphorbol 13-acetate (TPA), using the time series of gene expression data from DNA microarray experiments. KeyMolnet enables practical approaches to research into biological mechanisms, which in turn contribute to new discoveries in the medical, pharmaceutical and life sciences.
Export Options
About this article
Cite this article as:
Sato Hiromi, Ishida Seiichi, Toda Kyoko, Matsuda Rieko, Hayashi Yuzuru, Shigetaka Makoto, Fukuda Miki, Wakamatsu Yohko and Itai Akiko, New Approaches to Mechanism Analysis for Drug Discovery Using DNA Microarray Data Combined with KeyMolnet, Current Drug Discovery Technologies 2005; 2 (2) . https://dx.doi.org/10.2174/1570163054064701
DOI https://dx.doi.org/10.2174/1570163054064701 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Genetic and Peptide-Based Strategies Targeting the Bcl-2 Family, an Update
Recent Patents on DNA & Gene Sequences Isolation of Secreted microRNAs (miRNAs) from Cell-conditioned Media
MicroRNA The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer
Current Medicinal Chemistry Editorial
Recent Patents on Inflammation & Allergy Drug Discovery EGF-R Small Inhibitors and Anti-EGF-R Antibodies: Advantages and Limits of a New Avenue in Anticancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement
Current Pharmaceutical Design Polymorphisms of Human N-Acetyltransferases and Cancer Risk
Current Drug Metabolism Biochemical and Pharmacological Applications of Essential Oils in Human Health Especially in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Primary Management of Metastatic Colorectal Cancer with Bevacizumab. Review Article Focusing on Efficacy
Current Cancer Therapy Reviews Emulsomes Meet S-layer Proteins: An Emerging Targeted Drug Delivery System
Current Pharmaceutical Biotechnology Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Vitamin D Analogs as Modulators of Vitamin D Receptor Action
Current Topics in Medicinal Chemistry Targeted Therapies in Head and Neck Cancer: Past, Present and Future
Reviews on Recent Clinical Trials Editorial
Current Medical Imaging Advances in Immuno-PET for the Detection of Cancer and Assessment of Response to Therapy
Current Medicinal Chemistry Advances and Future Challenges in Adenoviral Vector Pharmacology and Targeting
Current Gene Therapy HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
Current Cancer Drug Targets Focal Adhesion Kinase as a Cancer Therapy Target
Anti-Cancer Agents in Medicinal Chemistry Molecular Profiling - An Essential Technology Enabling Personalized Medicine in Breast Cancer
Current Drug Targets Anti-Cancer Effect of Melatonin via Downregulation of Delta-like Ligand 4 in Estrogen-Responsive Breast Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery